Anti-PD-1/PD-L1 immunotherapy shows promise in treating periorbital NMSCs, suggesting new options for difficult cases.
Anti-PD-1/PD-L1 immunotherapy appears to be a promising option for treating locally advanced periocular BCC and cutaneous SCC, especially in cases where traditional treatments fail. Future research should involve nationwide databases or multi-institutional collaborations to validate the results and clarify the use of immune checkpoint inhibitors for periorbital NMSCs as adjuvant therapy.
No takes yet. Share an insight, caveat, or question.
Bineshfar et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: